X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4837) 4837
science & technology (4417) 4417
life sciences & biomedicine (4287) 4287
male (2900) 2900
female (2489) 2489
pyrazoles - adverse effects (2450) 2450
pyrazoles - therapeutic use (2435) 2435
middle aged (1761) 1761
aged (1635) 1635
animals (1555) 1555
celecoxib (1479) 1479
pyrazoles - pharmacology (1413) 1413
pyrazoles - administration & dosage (1401) 1401
adult (1367) 1367
treatment outcome (1003) 1003
pharmacology & pharmacy (1000) 1000
sulfonamides - adverse effects (888) 888
oncology (808) 808
abridged index medicus (736) 736
sulfonamides - therapeutic use (717) 717
pyrazoles (705) 705
aged, 80 and over (612) 612
hematology (605) 605
administration, oral (589) 589
anti-inflammatory agents, non-steroidal - adverse effects (589) 589
rats (547) 547
dose-response relationship, drug (533) 533
risk factors (532) 532
pyridones - adverse effects (523) 523
general & internal medicine (495) 495
care and treatment (494) 494
cardiovascular system & cardiology (488) 488
mice (476) 476
drug therapy (475) 475
medicine, general & internal (463) 463
pyridones - therapeutic use (459) 459
anticoagulants - adverse effects (450) 450
double-blind method (447) 447
cyclooxygenase inhibitors - adverse effects (440) 440
analysis (433) 433
medicine & public health (420) 420
research (391) 391
anticoagulants (388) 388
pyrazoles - pharmacokinetics (378) 378
anticoagulants - therapeutic use (377) 377
time factors (364) 364
pyrimidines - therapeutic use (363) 363
cardiac & cardiovascular systems (357) 357
pyridones - administration & dosage (355) 355
sulfonamides - administration & dosage (355) 355
protein kinase inhibitors - therapeutic use (347) 347
sulfonamides - pharmacology (347) 347
anti-inflammatory agents, non-steroidal - therapeutic use (345) 345
hemorrhage - chemically induced (341) 341
clinical trials (335) 335
adolescent (329) 329
piperidines - pharmacology (317) 317
rivaroxaban (317) 317
antineoplastic agents - therapeutic use (316) 316
patients (315) 315
pyridines - therapeutic use (310) 310
cyclooxygenase inhibitors - therapeutic use (309) 309
neurosciences & neurology (309) 309
atrial fibrillation - drug therapy (305) 305
clinical trials as topic (300) 300
pyrimidines - adverse effects (300) 300
randomized controlled trials as topic (297) 297
anticoagulants - administration & dosage (285) 285
young adult (283) 283
antineoplastic agents - adverse effects (279) 279
dabigatran (279) 279
lactones - adverse effects (277) 277
drug administration schedule (276) 276
atrial fibrillation (275) 275
stroke - prevention & control (272) 272
protein kinase inhibitors - adverse effects (268) 268
pyridines - adverse effects (268) 268
apixaban (267) 267
cancer (267) 267
piperidines - therapeutic use (266) 266
health aspects (265) 265
neurosciences (261) 261
receptor, cannabinoid, cb1 - antagonists & inhibitors (252) 252
retrospective studies (244) 244
drug interactions (242) 242
dosage and administration (241) 241
cyclooxygenase 2 (240) 240
cox-2 inhibitors (237) 237
cyclooxygenase 2 inhibitors - adverse effects (236) 236
internal medicine (233) 233
cyclooxygenase 2 inhibitors (232) 232
disease models, animal (232) 232
drug therapy, combination (229) 229
toxicology (226) 226
lung neoplasms - drug therapy (225) 225
cyclooxygenase 2 inhibitors - therapeutic use (218) 218
pharmacology/toxicology (217) 217
atrial fibrillation - complications (215) 215
leukemia, lymphocytic, chronic, b-cell - drug therapy (213) 213
rats, sprague-dawley (209) 209
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5502) 5502
German (171) 171
French (80) 80
Spanish (62) 62
Japanese (44) 44
Italian (37) 37
Chinese (17) 17
Russian (17) 17
Norwegian (14) 14
Dutch (11) 11
Polish (11) 11
Portuguese (9) 9
Danish (7) 7
Hungarian (7) 7
Swedish (6) 6
Czech (5) 5
Croatian (3) 3
Romanian (3) 3
Finnish (2) 2
Serbian (2) 2
Slovak (2) 2
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 08/2017, Volume 377, Issue 9, pp. 829 - 838
... with a 50% maximum inhibitory concentration of 1.9 nmol per liter in enzymatic analyses and with activity against the effects of several ALK mutations that confer... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 07/2016, Volume 134, Issue 3, pp. 248 - 261
.... In addition to familiarity with the dosing and monitoring of vitamin K antagonists, clinicians are accustomed to using vitamin K if there is a need to reverse the anticoagulant effect of vitamin K antagonists... 
anticoagulants | atrial fibrillation | venous thromboembolism | hemorrhage | Cardiac & Cardiovascular Systems | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Recombinant Proteins - therapeutic use | Plasma | Dabigatran - adverse effects | Pyrazoles - therapeutic use | Humans | Hemorrhage - prevention & control | Recombinant Proteins - adverse effects | Thiazoles - therapeutic use | Factor VIIa - therapeutic use | Arginine - analogs & derivatives | Dabigatran - therapeutic use | Thiazoles - adverse effects | Pyridines - adverse effects | Rivaroxaban - adverse effects | Factor Xa - therapeutic use | Rivaroxaban - therapeutic use | Factor Xa - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Piperazines - therapeutic use | Dabigatran - antagonists & inhibitors | Piperazines - adverse effects | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Blood Coagulation Factors - therapeutic use | Arginine - adverse effects | Pyridones - therapeutic use | Hemorrhage - chemically induced | Hemostatics - therapeutic use | Arginine - therapeutic use | Pyridones - adverse effects | Index Medicus | Abridged Index Medicus
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 04/2017, Volume 76, Issue 4, pp. 736 - 744
New molecularly targeted therapeutics are changing dermatologic therapy. Janus kinase–signal transducer and activator of transcription (JAK-STAT) is an... 
Dermatology | JAK-STAT | psoriasis | baricitinib | vitiligo | atopic dermatitis | JAK inhibitor | ruxolitinib | alopecia areata | tofacitinib | Life Sciences & Biomedicine | Science & Technology | Pyrazoles - therapeutic use | Dermatitis, Atopic - enzymology | Humans | Dermatologic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Dermatologic Agents - adverse effects | Anti-Inflammatory Agents - adverse effects | Anti-Inflammatory Agents - therapeutic use | Pyrroles - adverse effects | Vitiligo - drug therapy | Pyrroles - therapeutic use | Pyrazoles - adverse effects | Psoriasis - drug therapy | Vitiligo - enzymology | Azetidines - adverse effects | Alopecia Areata - enzymology | Skin Diseases - drug therapy | Clinical Trials as Topic | Dermatologic Agents - classification | Janus Kinases - antagonists & inhibitors | Dermatitis, Atopic - drug therapy | Alopecia Areata - drug therapy | Azetidines - therapeutic use | Signal Transduction - drug effects | Sulfonamides - therapeutic use | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Psoriasis - enzymology | Skin Diseases - enzymology | Medical colleges | Psoriasis | Atopic dermatitis | Formulae, receipts, prescriptions | Dermatologic agents | Pharmaceutical industry | Tyrosine | Interleukins | Interferon | Biological response modifiers | T cells | Index Medicus | Tofacitinib
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 2014, Volume 179, pp. 279 - 287
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 03/2012, Volume 107, Issue 3, pp. 584 - 589
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2019, Volume 381, Issue 19, pp. 1809 - 1819
Triple treatment with elexacaftor, tezacaftor, and ivacaftor in patients with cystic fibrosis who had one Phe508del allele and a minimal-function mutation... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cystic Fibrosis - physiopathology | Humans | Pyrrolidines - administration & dosage | Pyrrolidines - adverse effects | Male | Chloride Channel Agonists - adverse effects | Benzodioxoles - administration & dosage | Aminophenols - adverse effects | Indoles - administration & dosage | Forced Expiratory Volume | Sweat - chemistry | Young Adult | Pyridines - adverse effects | Quinolones - adverse effects | Adult | Benzodioxoles - adverse effects | Female | Child | Pyrazoles - adverse effects | Pyridines - administration & dosage | Double-Blind Method | Genotype | Chlorides - analysis | Pyrazoles - administration & dosage | Quinolones - administration & dosage | Indoles - adverse effects | Chloride Channel Agonists - administration & dosage | Cystic Fibrosis - genetics | Adolescent | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Mutation | Aminophenols - administration & dosage | Cystic Fibrosis - drug therapy | Drug Combinations | Cystic fibrosis | Ivacaftor | Genetic aspects | Drug therapy | Patient outcomes | Statistical analysis | Stock options | Clinical trials | Patients | Clinical outcomes | Quality of life | Proteins | Collaboration | Conductance | Genotypes | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 06/2013, Volume 368, Issue 25, pp. 2385 - 2394
Journal Article
The New England journal of medicine, ISSN 1533-4406, 10/2018, Volume 379, Issue 17, pp. 1599 - 1611
This companion article to the VX-445 report shows that VX-659, a new CFTR potentiator, when administered with tezacaftor and ivacaftor improved lung function,... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Pyrazoles - therapeutic use | Forced Expiratory Volume - drug effects | Humans | Pyrrolidines - adverse effects | Chloride Channel Agonists - therapeutic use | Male | Aminophenols - therapeutic use | Chloride Channel Agonists - adverse effects | Aminophenols - adverse effects | Pyrrolidines - pharmacology | Pyrrolidines - therapeutic use | Sweat - chemistry | Young Adult | Quinolones - adverse effects | Quinolones - therapeutic use | Adult | Benzodioxoles - adverse effects | Female | Benzodioxoles - therapeutic use | Pyrazoles - adverse effects | Pyrazoles - pharmacology | Double-Blind Method | Cells, Cultured | Genotype | Cystic Fibrosis Transmembrane Conductance Regulator - metabolism | Chlorides - analysis | Indoles - adverse effects | Cystic Fibrosis - genetics | Adolescent | Alleles | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Indoles - therapeutic use | Mutation | Cystic Fibrosis - drug therapy | Drug Combinations | Cystic fibrosis | Ivacaftor | Genetic aspects | Dosage and administration | Drug therapy | Epithelial cells | Chloride transport | Clinical trials | Recovery of function | Patients | Proteins | Genotype & phenotype | Conductance | Cystic fibrosis transmembrane conductance regulator | Protein transport | Sweat | Binding sites | Genotypes | Index Medicus | Abridged Index Medicus
Journal Article